Abstract: The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.

Abstract: The application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial genera Ileibacterium and Dubosiella, including their species I. valens (I. valens) and Dubosiella newyorkensis (D. newy), respectively, and closely related OTUs within the family Erysipelotrichaceae that resemble either Ileibacterium spp. or Dubosiella spp. with 90% 16S rRNA sequence identity, for modulating weight and intestinal inflammation and immunity (including modulating intestinal immune gene expression such as, e.g., modulating expression of ROR?T, IL-17A, IL-17F, RegIII?, Relm?, and Def?), as well as for treatment and diagnosis of (i) obesity and related conditions such as metabolic syndrome and diabetes mellitus; (ii) allergic and autoimmune diseases, and (iii) gastrointestinal disorders (such as, e.g., inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, and celiac disease).

Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.

Abstract: The present invention provides a pharmaceutical composition and a food product for inhibiting gastritis induced by gastric Helicobacter pylori, comprising Lactobacillus selected from a group composed of Lactobacillus rhamnosus GM-020 (also known as GMNL-74) with deposited number CCTCC M203098; Lactobacillus acidophilus GMNL-185 with deposited number CCTCC M2017764; and Lactobacillus plantarum GMNL-662 with deposited number CCTCC M2016571; and any two of the above bacteria.

Abstract: The present invention provides a composition for preventing stroke and ameliorating the severity of stroke and comprises an effective dose of Lactobacillus reuteri GMNL-89 and Lactobacillus paracasei GMNL-133; the accession number of Lactobacillus reuteri GMNL-89 is CCTCC M207154 and the accession number of Lactobacillus paracasei GMNL-133 is CCTCC M2011331. The composition can be taken as a dietary supplement and be given continuously after a stroke, and said composition has the effects of ameliorating cerebral infarction, motor function, and intestinal microbiota after a stroke.

Abstract: The invention relates generally to immunoassays, and more particularly to monoclonal antibodies and immunoassays for the differential detection and quantitation of a wild-type crystal protein, such as a wild-type-Cry1Ab, from Bacillus thuringiensis and hybrid crystal proteins, which comprise all or a significant portion of the wild-type Cry protein in complex biological samples comprising both the wild-type Cry protein and one or more of the hybrid Cry proteins.

Abstract: The present invention relates to a probiotic composition for preventing, improving or alleviating pancreatic cancer and a method for preventing, improving or alleviating the pancreatic cancer and its complications using the probiotic composition. The probiotic composition, which is consisted of specific strains and specific ratio of Lactobacillus paracasei to Lactobacillus reuteri, can significantly improve or alleviate various symptomatic indicators and severity of pancreatic cancer, thereby being applied on a method for preventing, improving or alleviating the pancreatic cancer and its complications using an oral composition including the Lactobacillus strains.

Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.

Abstract: A fusant F001 able to digest polysaccharides is formed by protoplast fusion between Bacillus amyloliquefaciens and Bacillus coagulans. The fusant F001 is deposited at NITE Patent Microorganisms Depositary (NPMD) in Japan with a deposit number NITE BP-02873.

Abstract: The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics.

Abstract: The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of S. mansoni (SM14) or related FABPs (Fatty Acid Binding Proteins), the peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity. More particularly, the present invention relates to a method for constructing active peptide fragments, peptide fragments, immunogenic compositions and diagnostic kits using peptide fragments.

Abstract: The invention provides compositions comprising one or more bacterial strains for use in a method of reducing the level of Enterobacteriaceae in the gastrointestinal tract.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing cancer.

Abstract: The present invention discloses beverage compositions comprising probiotic Bacillus coagulans and water soluble prebiotic fibers that have been subjected to treatments under extreme stress, temperature and pressure conditions like brewing or aeration wherein the spore viability is maintained post said treatments.

Abstract: The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation.

Abstract: The invention provides compositions comprising one or more bacterial strains for treating or preventing visceral hypersensitivity.

Abstract: The invention relates to malodor controlling bacteria and related methods and compositions for the control and prevention of malodor.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing Staphylococcus aureus infections.

Abstract: Provided is a genetically engineered Candida utilis capable of degrading and utilizing kitchen waste. The genetically engineered Candida utilis is obtained by using a Candida utilis multigene co-expression vector to integrate alpha-amylase, glucoamylase and acid protease genes into the Candida utilis genome and to correctly express such three enzymes.